A research team headed by two School of Medicine professors has developed a new method for tracking adverse drug interactions using queries from Internet search engines like Google and Bing. The team’s discovery offers an alternative to the Food and Drug Administration’s (FDA) Adverse Event Reporting System (AERS).
Cuéllar said that growing up along the U.S.-Mexico border had a profound influence on his understanding of the world and prompted his desire to study politics and governance.
Palo Alto resident Christopher Bui is suing the Stanford Blood Center because of an infection he said he acquired after donating blood on April 10, 2008.
Using a computer model of the hepatitis C disease, Stanford researchers have shown that two new drugs intended to target the virus are cost-effective for patients suffering from advanced hepatitis C, despite some significant side effects.
Two studies from the School of Medicine, published Monday in Annals of Internal Medicine, revealed that an expensive blood-clotting drug intended only for hemophilia patients has been mainly prescribed for patients without this disorder. This practice, however, may pose certain health risks.